SCHEMBL30765619

SCHEMBL30765619

CC(C)c1ncc(N[C@H](C)c2ccc3oc4ccccc4c3c2)c(=O)n1CC(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
ELANE P08246 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
KDM4E B2RXH2 1/20 0.36
ASPH Q12797 1/20 0.36
RIOX2 Q8IUF8 1/20 0.36
KDM8 Q8N371 1/20 0.36
MMP12 P39900 2/20 0.36
MMP13 P45452 2/20 0.36
NPY5R Q15761 1/20 0.36
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35
GABRB2 P47870 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31558435 0.88 ELANE (0.45) LMNAELANEHDAC6GABRPGABRD
SCHEMBL30765957 0.88 ALDH1A1 (0.38) LMNAELANEKDM4EGABRPGABRD
SCHEMBL30765814 0.87 LMNA (0.39) LMNAHDAC6KDM4EGABRPGABRD
SCHEMBL31558409 0.86 POLB (0.36) LMNAELANEHDAC6KDM4EASPH
SCHEMBL30765770 0.86 LMNA (0.38) LMNAHDAC6KDM4EASPHRIOX2
SCHEMBL30765863 0.86 GAA (0.38) LMNAHDAC6KDM4EASPHRIOX2
SCHEMBL30765710 0.86 LMNA (0.38) LMNAHDAC6KDM4EASPHRIOX2
SCHEMBL30765510 0.86 L3MBTL1 (0.41) LMNAELANEGABRPGABRDGABRA1
SCHEMBL30765456 0.85 ELANE (0.35) LMNAELANEHDAC6KDM4EASPH
SCHEMBL30766151 0.84 ELANE (0.37) LMNAELANEHDAC6GABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed